- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04679376
Statins for the Treatment of NASH (STAT NASH)
April 8, 2024 updated by: Manal F. Abdelmalek, Mayo Clinic
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christopher Kigongo
- Phone Number: 507-266-1998
- Email: Kigongo.Christopher@mayo.edu
Study Contact Backup
- Name: Amy Olofson
- Phone Number: 507-538-6547
- Email: Olofson.Amy@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Minnesota
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Active, not recruiting
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Definite NASH on a liver biopsy obtained ≤ 90 days prior to randomization with a NAFLD activity score (NAS) of ≥ 4 with at least 1 in each component of the NAS according to NASH CRN grading52
- Fibrosis stage ≥ 2 as assessed by liver biopsy
- Not currently on statin therapy
- Provision of written informed consent
- Agree to use of effective contraceptive measures if female of child bearing potential.
Exclusion Criteria:
- The presence of any of the following will exclude a subject from study enrollment: Any chronic liver disease other than NASH (i.e., drug-induced, viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, A1AT deficiency, Wilsons disease)
- Cirrhosis, as assessed clinically or histologically
- Presence of vascular liver disease
- BMI ≤ 25 kg/m2
- Excessive alcohol use (> 20 g/day) within the past 2 years
- AST or ALT > 250 U/L.
- Type 1 diabetes mellitus
- Bariatric surgery in the past 5 years.
- Weight gain of > 5% in past 6 months or > 10% change in past 12 months.
- Inadequate venous access
- HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or HCV RNA positive.
- Receiving an elemental diet or parenteral nutrition
- Chronic pancreatitis or pancreatic insufficiency
- Any history of complications of cirrhosis (i.e. ascites, hepatic encephalopathy, or portal hypertensive bleeding), even if absent or optimized with medical management at time of screening
- Concurrent conditions: a) Inflammatory bowel disease, b) Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of screening, c) Ongoing infectious, immune mediated disease within previously 1 years, d) Any malignant disease (other than basal cell carcinoma of the skin) within previous 5 years, e) Prior solid organ transplant, f) Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.
- Concurrent medications including: a) Anti-NASH therapy(s) initiated after the liver biopsy diagnosing NASH. Anti-NASH therapies include S-adenosyl methionine (SAMe), milk thistle, and vitamin E at dose of ≥ 400 IU/day; b) Antidiabetic mediation which may impact NASH histology started in the past 12 months including thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or glucagon-like peptide 1 analogs; c) Immune modulatory agents including systemic steroids, methotrexate, anti-TNF-α therapies (infliximab, adalimumab, etanercept) or anti-integrin therapy (namixilab).
- Self-reported or known marijuana or illicit drug use 30 days before the screening
- The following laboratory abnormalities within 90 days of screening: a) HbA1C > 9.0%, b) Neutrophil count < 1.0 x 109/L, c) Platelets < 100 109/L, d) Hemoglobin < 10 g/dl, e) Albumin < 3.5 g, f) Prolonged international normalized ratio (INR), g) Any elevation of bilirubin above normal (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction), h) Serum creatinine > 1.5 mg/dl, i) Creatinine clearance ≤ 50 ml/minute calculated by Crockroft-Gault or creatinine > 1.5x upper limit of normal
- Pregnancy or breastfeeding.
- Women, of childbearing age, who are not willing to practice effective contraception (i.e., barrier, oral contraceptives, or past medical history of hysterectomy) for the 48-week duration of the trial and for 1 month after the first administration of the drug.
- Participation in an investigational drug study within past 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: Atorvastatin Treatment
Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive atorvastatin for 96 weeks
|
40 mg daily administered orally in tablet or capsule form
Other Names:
|
Placebo Comparator: Group 2: Placebo
Subjects who have a histology-proved NASH with fibrosis stage 2 or higher will receive a placebo for 96 weeks
|
Administered daily orally in tablet or capsule form, contains no active medicine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NASH as measured by improvement in NAS score Improvement in NAS score (≥ 2 points) with no worsening in fibrosis stage (≥1 point) OR improvement in fibrosis with no worsening of NASH (change in the NAS score of ≤ 0 points).
Time Frame: Baseline, 96 weeks
|
One overall score of NASH improvement will be derived from improvement in NAS score OR no worsening in fibrosis.
|
Baseline, 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NASH resolution as measured by (diagnosis by pathologist) (from definite- to not- NASH).....
Time Frame: Baseline, 96 weeks
|
Histological change from NASH to No NASH
|
Baseline, 96 weeks
|
Change in fibrosis stage as measured by change in stage
Time Frame: Baseline, 96 weeks
|
Ordinal variable
|
Baseline, 96 weeks
|
Change in each component of NASH histologic features as measured by presence or ab presence or absence of features or their severity.
Time Frame: Baseline, 96 weeks
|
Existing features may improve in severity or disappear as an indication of improvement of NASH.
|
Baseline, 96 weeks
|
Change in serum aminotransferase (ALT) and aspartate aminotransferase (AST) levels as measured by plasma concentrations
Time Frame: Baseline, 96 weeks
|
Baseline, 96 weeks
|
|
Change in makers of hepatic fibrosis markers as measured by (FIB-4,51 liver stiffness by Fibroscan®)
Time Frame: Baseline, 96 weeks
|
Baseline, 96 weeks
|
|
Change in capture attention parameter (CAP) score (with Fibroscan®)
Time Frame: Baseline, 96 weeks
|
Baseline, 96 weeks
|
|
Serum creatine phosphokinase (CPK) as measured by serum concentration
Time Frame: Baseline, 96 weeks
|
Baseline, 96 weeks
|
|
Change in serum lipids as measured by serum concentration
Time Frame: Baseline, 96 weeks
|
Baseline, 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Manal Abdelmalek, MD, MPH, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 25, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
December 17, 2020
First Submitted That Met QC Criteria
December 17, 2020
First Posted (Actual)
December 22, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-007824
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NASH - Nonalcoholic Steatohepatitis
-
Milton S. Hershey Medical CenterNot yet recruitingLiver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrosis | Cirrhosis | NAFLD | NASH - Nonalcoholic Steatohepatitis | NASH
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on Atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina